CRC Research Update — July 03, 2026
Today's colorectal cancer research highlights
kras-g12c
A collection of 41 issues
CRC Research Update — June 06, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 04, 2026
Today's colorectal cancer research highlights
This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy
Skip to content
The CRC Digest
◆ TRIAL DATA
Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy — Journal of Clinical Oncology
. This blood-based test could help doctors identify which patients are responding to treatment without waiting for scans.
What this means
If you have a KRAS G12C
CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
ctDNA clearance as early biomarker in KRAS G12C colorectal cancer
Skip to content
The CRC Digest
ctDNA clearance as early biomarker in KRAS G12C colorectal cancer
Phase 3 CodeBreaK 300 results link circulating tumor DNA clearance to efficacy and prognosis with sotorasib plus panitumumab. (JCO)
This content is informational only and does not constitute medical advice.
Always consult your oncologist
CRC Research Update — May 25, 2026
Today's colorectal cancer research highlights
KRAS G12D-targeted therapy tested in preclinical models
Skip to content
The CRC Digest
KRAS G12D-targeted therapy tested in preclinical models
A nanomedicine delivering a KRAS G12D inhibitor showed promise in laboratory models of metastatic colorectal cancer. (Journal of Controlled Release)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care
CRC Research Finding
Skip to content
The CRC Digest
◇ Experimental nanomedicine targets KRAS G12D mutation in metastatic colorectal cancer
Preclinical research describes a macrophage-hitchhiking delivery system combining gemcitabine and a KRAS G12D inhibitor that improved drug delivery to lung metastases and triggered immune responses in colorectal cancer models. (Journal of Controlled Release)
This